These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21042730)

  • 1. FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.
    Wang B; Kokhaei P; Mellstedt H; Liljefors M
    Int J Oncol; 2010 Dec; 37(6):1599-606. PubMed ID: 21042730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.
    Calemma R; Ottaiano A; Trotta AM; Nasti G; Romano C; Napolitano M; Galati D; Borrelli P; Zanotta S; Cassata A; Castello G; Iaffaioli VR; Scala S
    J Transl Med; 2012 Nov; 10():232. PubMed ID: 23171437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
    Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
    Park SJ; Hong YS; Lee JL; Ryu MH; Chang HM; Kim KP; Ahn YC; Na YS; Jin DH; Yu CS; Kim JC; Kang YK; Kim TW
    Oncology; 2012; 82(2):83-9. PubMed ID: 22327884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
    Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
    Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
    Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
    J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
    Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
    Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
    J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphisms of FcγRIIA, FcγRIIIA and FcγRIIB in patients with immune thrombocytopenia and their clinical significance].
    Zhu Y; Zhuang Y; Yang GH; Qiang XF; Yang L; Shen YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):135-9. PubMed ID: 23484707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
    Rodríguez J; Zarate R; Bandres E; Boni V; Hernández A; Sola JJ; Honorato B; Bitarte N; García-Foncillas J
    Eur J Cancer; 2012 Aug; 48(12):1774-80. PubMed ID: 22305465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications?
    Aksu K; Kitapcioglu G; Keser G; Berdeli A; Karabulut G; Kobak S; Ozmen M; Inal V; Kabasakal Y; Oksel F; Kocanaogullari H; Doganavsargil E
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S77-83. PubMed ID: 19026120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
    Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
    BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
    Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
    Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.
    Sclafani F; Gonzalez de Castro D; Cunningham D; Hulkki Wilson S; Peckitt C; Capdevila J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Begum R; Thomas J; Oates J; Chau I
    Clin Cancer Res; 2014 Sep; 20(17):4511-9. PubMed ID: 24987061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes.
    Dijstelbloem HM; Bijl M; Fijnheer R; Scheepers RH; Oost WW; Jansen MD; Sluiter WJ; Limburg PC; Derksen RH; van de Winkel JG; Kallenberg CG
    Arthritis Rheum; 2000 Dec; 43(12):2793-800. PubMed ID: 11145038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.
    Weng WK; Weng WK; Levy R
    Leuk Lymphoma; 2009 Sep; 50(9):1494-500. PubMed ID: 19672774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.
    Manger K; Repp R; Jansen M; Geisselbrecht M; Wassmuth R; Westerdaal NA; Pfahlberg A; Manger B; Kalden JR; van de Winkel JG
    Ann Rheum Dis; 2002 Sep; 61(9):786-92. PubMed ID: 12176802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.